Abbott Laboratories (NYSE:ABT) is included among the 14 Best Pharma Dividend Stocks to Buy in 2026. On December 22, Abbott ...

Abbott Elementary is going to the mall (and not to shop) — get the scoop on the big transition, and watch an exclusive sneak ...

Abbott can now compete with Medtronic, Boston Scientific and J&J in the U.S. for the fast-growing pulsed field ablation ...

The Food and Drug Administration clearance and CE mark position Abbott to sell its Amplatzer Piccolo Delivery System in the U ...

The FDA approved Abbott's Volt PFA System for atrial fibrillation, supported by VOLT-AF trial data showing strong safety and ...

Abbott will soon enter the competitive U.S. pulsed field ablation (PFA) market, having just received FDA approval for its ...

Abbott Laboratories announced a $21 billion deal Thursday morning to acquire Exact Sciences, the maker of Cologuard — its largest acquisition in a decade. The deal will allow Abbott — which makes ...

Abbott Laboratories' diabetes care segment recently added new products to its lineup. It should remain one of the company's key growth drivers over the long run. There are other good reasons to invest ...

Abbott Laboratories (NYSE:ABT) ranks among the best slow growth stocks to invest in. UBS reaffirmed its Buy rating and $158 price target for Abbott Laboratories (NYSE:ABT) on November 21 in response ...

Tehuan Harris is a news and features journalist at Collider, reporting and writing about all things music and reality TV (sometimes). She is a talented journalist and a natural storyteller who writes ...

Abbott’s lawyers at Jones Day negotiated secret settlements and used scorched earth tactics with families whose infants fell ill after consuming powdered formula. Credit...Max Guther Supported by By ...

Abbott (NYSE: ABT) announced today that the FDA approved its Volt pulsed field ablation (PFA) system to treat patients with AFib.